Drug Discovery


Drug Discovery Market Research Reports Analysis and Trends

Publication Single User License (PDF) Price
TIM-3 Antagonist -Pipeline Insights, 2015

TIM-3 Antagonist -Pipeline Insights, 2015

Date Published: Aug 24 2015
TIM-3 Antagonist- Pipeline Insights, 2015 report provides the in-depth analysis of the pipeline assets across the TIM-3 Antagonist. The main objective of this report to track competitor pipeline molecules, related research activities, technology, collaborations, in-licensing and out-licensing deals. The TIM-3 Antagonist Report helps to identify emerging players with potentially strong product information and create effective counter-strategies to gain competitive advantage.
 
$575.00
OX-40 Agonist -Pipeline Insights, 2015

OX-40 Agonist -Pipeline Insights, 2015

Date Published: Aug 24 2015
OX-40 Antagonist- Pipeline Insights, 2015 report provides the in-depth analysis of the pipeline assets across the OX-40 Antagonist. The main objective of this report to track competitor pipeline molecules, related research activities, technology, collaborations, in-licensing and out-licensing deals. The OX-40 AgonistReport helps to identify emerging players with potentially strong product information and create effective counter-strategies to gain competitive advantage.
 
$675.00
LAG-3 Antagonist -Pipeline Insights, 2015

LAG-3 Antagonist -Pipeline Insights, 2015

Date Published: Aug 24 2015
LAG-3 Antagonist- Pipeline Insights, 2015 report provides the in-depth analysis of the pipeline assets across the LAG-3 Antagonist. The main objective of this report to track competitor pipeline molecules, related research activities, technology, collaborations, in-licensing and out-licensing deals. The LAG-3 Antagonist Report helps to identify emerging players with potentially strong product information and create effective counter-strategies to gain competitive advantage.
 
$675.00
LAG-3 Antagonists, TIM-3 Antagonists & OX40 Agonists -Pipeline Insights, 2015

LAG-3 Antagonists, TIM-3 Antagonists & OX40 Agonists -Pipeline Insights, 2015

Date Published: Jul 28 2015
DelveInsight’s, LAG-3 Antagonists, TIM-3 Antagonists & OX40 Agonists- Pipeline Insights, 2015, provides the in-depth analysis of the pipeline assets across the LAG-3 Antagonists, TIM-3 Antagonists & OX40 Agonists. The main objective of this report to track competitor pipeline molecules, related research activities, technology, collaborations, in-licensing and out-licensing deals.
$1,250.00
Nonalcoholic Steatohepatitis (NASH) - Pipeline Analysis

Nonalcoholic Steatohepatitis (NASH) - Pipeline Analysis

Date Published: Jul 17 2015
 “Nonalcoholic steatohepatitis (NASH) Pipeline Analysis” gives comprehensive insight on the various drugs being developed for the treatment of NASH. The report covers all the drugs being developed in various phases (Discovery, Preclinical & Clinical development). The pipeline focuses on novel medicines covering small molecules, monoclonal antibodies, Recombinant proteins and RNA-based therapeutics, but excludes Off-label, symptom relief drugs, generic combinations.
$3,600.00
Chimeric Antigen Receptor (CAR) T cell Immunotherapy- Competitive Landscape, Technology and Pipeline Analysis, 2015

Chimeric Antigen Receptor (CAR) T cell Immunotherapy- Competitive Landscape, Technology and Pipeline Analysis, 2015

Date Published: Jul 1 2015
$1,750.00
 Systemic Mastocytosis-Pipeline Insights, 2015

Systemic Mastocytosis-Pipeline Insights, 2015

Date Published: May 14 2015

Summary
DelveInsight’s, Systemic Mastocytosis- Pipeline Insights, 2015, provides the in-depth analysis of the pipeline assets across the Systemic Mastocytosis. The main objective of this report to track competitor pipeline molecules, related research activities, technology, collaborations, in-licensing and out-licensing deals. The Systemic Mastocytosis Report helps to identify emerging players with potentially strong product information and create effective counter-strategies to gain competitive advantage.

$1,250.00
HIF-1 Alpha Inhibitors -Pipeline Insights, 2015

HIF-1 Alpha Inhibitors -Pipeline Insights, 2015

Date Published: May 14 2015

Summary
DelveInsight’s, HIF-1 Alpha Inhibitors- Pipeline Insights, 2015, provides the in-depth analysis of the pipeline assets across the HIF-1 Alpha Inhibitors. The main objective of this report to track competitor pipeline molecules, related research activities, technology, collaborations, in-licensing and out-licensing deals. The HIF-1 Alpha Inhibitors Report helps to identify emerging players with potentially strong product information and create effective counter-strategies to gain competitive advantage.

$1,250.00
 Autism-Pipeline Insights, 2015

Autism-Pipeline Insights, 2015

Date Published: May 14 2015

Summary
DelveInsight’s, Autism- Pipeline Insights, 2015, provides the in-depth analysis of the pipeline assets across the Autism. The main objective of this report to track competitor pipeline molecules, related research activities, technology, collaborations, in-licensing and out-licensing deals. The Autism Report helps to identify emerging players with potentially strong product information and create effective counter-strategies to gain competitive advantage.

$1,250.00
 Osteosarcoma-Pipeline Insights, 2015

Osteosarcoma-Pipeline Insights, 2015

Date Published: May 14 2015

Summary
DelveInsight’s, Osteosarcoma- Pipeline Insights, 2015, provides the in-depth analysis of the pipeline assets across the Osteosarcoma. The main objective of this report to track competitor pipeline molecules, related research activities, technology, collaborations, in-licensing and out-licensing deals. The Osteosarcoma Report helps to identify emerging players with potentially strong product information and create effective counter-strategies to gain competitive advantage.

$1,250.00
Checkpoint Kinase 2 (Chk2) Inhibitors -Pipeline Insights, 2015

Checkpoint Kinase 2 (Chk2) Inhibitors -Pipeline Insights, 2015

Date Published: May 14 2015

Summary
DelveInsight’s, Checkpoint Kinase 2 (Chk2) Inhibitors- Pipeline Insights, 2015, provides the in-depth analysis of the pipeline assets across the Checkpoint Kinase 2 (Chk2) Inhibitors. The main objective of this report to track competitor pipeline molecules, related research activities, technology, collaborations, in-licensing and out-licensing deals. The Checkpoint Kinase 2 (Chk2) Inhibitors Report helps to identify emerging players with potentially strong product information and create effective counter-strategies to gain competitive advantage.

$1,250.00
Secretase inhibitors -Pipeline Insights, 2015

Secretase inhibitors -Pipeline Insights, 2015

Date Published: May 14 2015

Summary
DelveInsight’s, Secretase inhibitors- Pipeline Insights, 2015, provides the in-depth analysis of the pipeline assets across the Secretase inhibitors. The main objective of this report to track competitor pipeline molecules, related research activities, technology, collaborations, in-licensing and out-licensing deals. The Secretase inhibitors Report helps to identify emerging players with potentially strong product information and create effective counter-strategies to gain competitive advantage.

$1,250.00
 Hyperphosphatemia-Pipeline Insights, 2015

Hyperphosphatemia-Pipeline Insights, 2015

Date Published: May 14 2015

Summary
DelveInsight’s, Hyperphosphatemia- Pipeline Insights, 2015, provides the in-depth analysis of the pipeline assets across the Hyperphosphatemia. The main objective of this report to track competitor pipeline molecules, related research activities, technology, collaborations, in-licensing and out-licensing deals. The Hyperphosphatemia Report helps to identify emerging players with potentially strong product information and create effective counter-strategies to gain competitive advantage.

$1,250.00
Adenosine A2A Receptor Antagonists -Pipeline Insights, 2015

Adenosine A2A Receptor Antagonists -Pipeline Insights, 2015

Date Published: May 14 2015

Summary
DelveInsight’s, Adenosine A2A Receptor Antagonists- Pipeline Insights, 2015, provides the in-depth analysis of the pipeline assets across the Adenosine A2A Receptor Antagonists. The main objective of this report to track competitor pipeline molecules, related research activities, technology, collaborations, in-licensing and out-licensing deals. The Adenosine A2A Receptor Antagonists Report helps to identify emerging players with potentially strong product information and create effective counter-strategies to gain competitive advantage.

$1,250.00
mGlu2 Antagonists -Pipeline Insights, 2015

mGlu2 Antagonists -Pipeline Insights, 2015

Date Published: May 14 2015

Summary
DelveInsight’s, mGlu2 Antagonists- Pipeline Insights, 2015, provides the in-depth analysis of the pipeline assets across the mGlu2 Antagonists. The main objective of this report to track competitor pipeline molecules, related research activities, technology, collaborations, in-licensing and out-licensing deals. The mGlu2 Antagonists Report helps to identify emerging players with potentially strong product information and create effective counter-strategies to gain competitive advantage.

$1,250.00
 Cryptococcosis-Pipeline Insights, 2015

Cryptococcosis-Pipeline Insights, 2015

Date Published: May 14 2015

Summary
DelveInsight’s, Cryptococcosis- Pipeline Insights, 2015, provides the in-depth analysis of the pipeline assets across the Cryptococcosis. The main objective of this report to track competitor pipeline molecules, related research activities, technology, collaborations, in-licensing and out-licensing deals. The Cryptococcosis Report helps to identify emerging players with potentially strong product information and create effective counter-strategies to gain competitive advantage.

$1,250.00
 Reperfusion Injury-Pipeline Insights, 2015

Reperfusion Injury-Pipeline Insights, 2015

Date Published: May 14 2015

Summary
DelveInsight’s, Reperfusion Injury- Pipeline Insights, 2015, provides the in-depth analysis of the pipeline assets across the Reperfusion Injury. The main objective of this report to track competitor pipeline molecules, related research activities, technology, collaborations, in-licensing and out-licensing deals. The Reperfusion Injury Report helps to identify emerging players with potentially strong product information and create effective counter-strategies to gain competitive advantage.

$1,250.00
Fibroblast Growth Factor Receptor 2 (FGFR2) Inhibitors -Pipeline Insights, 2015

Fibroblast Growth Factor Receptor 2 (FGFR2) Inhibitors -Pipeline Insights, 2015

Date Published: May 14 2015

Summary

$1,250.00
 Moderate Psoriasis-Pipeline Insights, 2015

Moderate Psoriasis-Pipeline Insights, 2015

Date Published: May 14 2015

Summary
DelveInsight’s, Moderate Psoriasis- Pipeline Insights, 2015, provides the in-depth analysis of the pipeline assets across the Moderate Psoriasis. The main objective of this report to track competitor pipeline molecules, related research activities, technology, collaborations, in-licensing and out-licensing deals. The Moderate Psoriasis Report helps to identify emerging players with potentially strong product information and create effective counter-strategies to gain competitive advantage.

$1,250.00
Bcl-w Protein Inhibitors -Pipeline Insights, 2015

Bcl-w Protein Inhibitors -Pipeline Insights, 2015

Date Published: May 14 2015

Summary
DelveInsight’s, Bcl-w Protein Inhibitors- Pipeline Insights, 2015, provides the in-depth analysis of the pipeline assets across the Bcl-w Protein Inhibitors. The main objective of this report to track competitor pipeline molecules, related research activities, technology, collaborations, in-licensing and out-licensing deals. The Bcl-w Protein Inhibitors Report helps to identify emerging players with potentially strong product information and create effective counter-strategies to gain competitive advantage.

$1,250.00

Pages

Shopping cart

0 Items $0.00
Not able to find what you are looking for?
Call Us
WHY CHOOSE MARKET RESEARCH REPORTS?
1
Trusted By Leaders
2
Shop With Confidence
3
Customer Centric
4
Personalized Solutions
5
Secure Checkout

User login

Clients Who Trust Us

Orange, Google, Microsoft, Barclays, CassidianIntel, TPG, Elit Net, Cross Business Producers, AcmavolpakP&G, Cisco, Gemalto, General Insurance Corporation of India, Aviva, Cognizant, InoxWindB. Braun, Cobham, fiserv, Harris, Wipro, AonAl Meera, Nomura Research Institute, Tata Consultancy Services, Amara Raja, Hiranandani EnergyMunich Re, Lotte Chemical, National Post, First Data